Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
1.35
-0.01 (-0.74%)
After Hours: 1.28 -0.07 (-5.19%)
Dec 18, 6:43PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.30 - 1.41
52 week 1.28 - 8.41
Open 1.38
Vol / Avg. 4.02M/2.27M
Mkt cap 269.49M
P/E     -
Div/yield     -
EPS -1.47
Shares 195.22M
Beta 2.48
Inst. own 66%
Feb 18, 2015
Q4 2014 Exelixis Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 2, 2014
Exelixis Inc at Piper Jaffray Healthcare Conference
Nov 18, 2014
Exelixis Inc at Stifel Healthcare Conference
Nov 4, 2014
Q3 2014 Exelixis Inc Earnings Call - Webcast
Nov 4, 2014
Q3 2014 Exelixis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -994.44% -781.03%
Operating margin -819.81% -640.54%
EBITD margin - -626.72%
Return on average assets -60.88% -39.98%
Return on average equity - -134.98%
Employees 227 -
CDP Score - -

Address

210 E. GRAND AVE
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-8377000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Discovery Research, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Jeffrey J. Hessekiel J.D. Executive Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. Executive Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Pamela A. Simonton J.D. Executive Vice President
Age: 64
Bio & Compensation  - Reuters
Deborah Burke Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Controller
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq Independent Director
Age: 70
Bio & Compensation  - Reuters
Alan M. Garber M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters